Compare Stocks: JANX, CELC, ABCL, and XENE

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCL AbCellera Biologics	$12.31 -2.7%	$9.55	$2.74 ▼ $13.18	$3.88B	1.32	4.13 million shs	3.85 million shs
CELC Celcuity	$79.99 -4.9%	$89.02	$44.42 ▼ $151.02	$4.12B	0.19	798,986 shs	739,309 shs
JANX Janux Therapeutics	$16.52 -5.4%	$17.05	$12.12 ▼ $35.34	$1.07B	2.53	933,115 shs	967,415 shs
XENE Xenon Pharmaceuticals	$36.56 -6.5%	$60.36	$35.97 ▼ $72.66	$3.78B	0.61	1.77 million shs	3.17 million shs

7 Stocks That Will Be Magnificent in 2026

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCL AbCellera Biologics	-2.69%	+5.48%	+16.02%	+84.83%	+151.22%
CELC Celcuity	-4.89%	-3.14%	-11.90%	-16.62%	+52.36%
JANX Janux Therapeutics	-5.44%	+1.66%	-11.18%	+13.31%	-28.11%
XENE Xenon Pharmaceuticals	-6.47%	-35.59%	-39.63%	-35.61%	-2.01%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABCL AbCellera Biologics	$12.31 -2.7%	$9.55	$2.74 ▼ $13.18	$3.88B	1.32	4.13 million shs	3.85 million shs
CELC Celcuity	$79.99 -4.9%	$89.02	$44.42 ▼ $151.02	$4.12B	0.19	798,986 shs	739,309 shs
JANX Janux Therapeutics	$16.52 -5.4%	$17.05	$12.12 ▼ $35.34	$1.07B	2.53	933,115 shs	967,415 shs
XENE Xenon Pharmaceuticals	$36.56 -6.5%	$60.36	$35.97 ▼ $72.66	$3.78B	0.61	1.77 million shs	3.17 million shs

7 Stocks That Will Be Magnificent in 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABCL AbCellera Biologics	-2.69%	+5.48%	+16.02%	+84.83%	+151.22%
CELC Celcuity	-4.89%	-3.14%	-11.90%	-16.62%	+52.36%
JANX Janux Therapeutics	-5.44%	+1.66%	-11.18%	+13.31%	-28.11%
XENE Xenon Pharmaceuticals	-6.47%	-35.59%	-39.63%	-35.61%	-2.01%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABCL AbCellera Biologics	2.71	Moderate Buy	$12.83	4.25% Upside
CELC Celcuity	2.83	Moderate Buy	$154.75	93.46% Upside
JANX Janux Therapeutics	2.67	Moderate Buy	$36.46	120.71% Upside
XENE Xenon Pharmaceuticals	2.94	Moderate Buy	$70.93	94.02% Upside

Current Analyst Ratings Breakdown

Latest JANX, CELC, ABCL, and XENE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/18/2026	XENE Xenon Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
9/18/2026	XENE Xenon Pharmaceuticals	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$69.00 ➝ $64.00
9/18/2026	XENE Xenon Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$90.00 ➝ $46.00
9/18/2026	XENE Xenon Pharmaceuticals	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$90.00 ➝ $46.00
9/18/2026	XENE Xenon Pharmaceuticals	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$81.00 ➝ $70.00
9/18/2026	XENE Xenon Pharmaceuticals	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$71.00 ➝ $55.00
9/18/2026	XENE Xenon Pharmaceuticals	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$97.00 ➝ $90.00
9/18/2026	XENE Xenon Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$78.00 ➝ $60.00
9/17/2026	CELC Celcuity	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Overweight	$157.00
9/1/2026	CELC Celcuity	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
8/24/2026	JANX Janux Therapeutics	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Peer Perform ➝ Outperform	$23.00

(Data available from 9/24/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABCL AbCellera Biologics	$66.17M	57.04	N/A	N/A	$3.23 per share	3.81
CELC Celcuity	N/A	N/A	N/A	N/A	$2.17 per share	N/A
JANX Janux Therapeutics	$10M	101.00	N/A	N/A	$15.91 per share	1.04
XENE Xenon Pharmaceuticals	$7.50M	471.23	N/A	N/A	$7.53 per share	4.86

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABCL AbCellera Biologics	-$146.41M	-$0.54	N/A	N/A	N/A	-248.83%	-17.49%	-12.36%	11/5/2026 (Estimated)
CELC Celcuity	-$177.04M	-$4.30	N/A	N/A	N/A	N/A	-350.78%	-41.54%	11/11/2026 (Estimated)
JANX Janux Therapeutics	-$113.62M	-$1.64	N/A	N/A	N/A	N/A	-11.89%	-11.13%	11/5/2026 (Estimated)
XENE Xenon Pharmaceuticals	-$345.91M	-$4.74	N/A	N/A	N/A	N/A	-43.98%	-41.72%	11/2/2026 (Estimated)

Latest JANX, CELC, ABCL, and XENE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	CELC Celcuity	-$1.16	-$1.44	-$0.28	-$1.44	$4.42 million	N/A
8/6/2026	Q2 2026	JANX Janux Therapeutics	-$0.2513	-$0.35	-$0.0987	-$0.35	$19.08 million	$10.27 million
8/6/2026	Q2 2026	XENE Xenon Pharmaceuticals	-$1.16	-$1.11	+$0.05	-$1.11	$1.67 million	N/A
8/5/2026	Q2 2026	ABCL AbCellera Biologics	-$0.1640	-$0.18	-$0.0160	-$0.18	$7.85 million	$4.05 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABCL AbCellera Biologics	N/A	N/A	N/A	N/A	N/A
CELC Celcuity	N/A	N/A	N/A	N/A	N/A
JANX Janux Therapeutics	N/A	N/A	N/A	N/A	N/A
XENE Xenon Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABCL AbCellera Biologics	N/A	12.77	12.77
CELC Celcuity	6.04	8.93	8.93
JANX Janux Therapeutics	N/A	16.35	16.35
XENE Xenon Pharmaceuticals	N/A	21.01	21.02

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ABCL AbCellera Biologics	61.42%
CELC Celcuity	63.33%
JANX Janux Therapeutics	75.39%
XENE Xenon Pharmaceuticals	95.45%

Insider Ownership

Company	Insider Ownership
ABCL AbCellera Biologics	28.40%
CELC Celcuity	13.33%
JANX Janux Therapeutics	7.90%
XENE Xenon Pharmaceuticals	2.91%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ABCL AbCellera Biologics	562	306.61 million	219.53 million	Optionable
CELC Celcuity	155	48.93 million	42.41 million	Optionable
JANX Janux Therapeutics	113	61.14 million	56.31 million	Optionable
XENE Xenon Pharmaceuticals	370	96.67 million	93.85 million	Optionable

JANX, CELC, ABCL, and XENE Headlines

Recent News About These Companies

Bank of America Corp DE Buys New Holdings in Xenon Pharmaceuticals Inc. $XENE

3 hours ago | marketbeat.com

XENE Investors Have Opportunity to Join Xenon Pharmaceuticals Inc. Fraud Investigation with SBS Law

September 22 at 12:23 AM | businesswire.com

Xenon Pharmaceuticals (XENE) Seeks Epilepsy Approval. Can its Drug Overcome a Depression Setback?

September 22 at 8:50 PM | insidermonkey.com

Xenon Pharmaceuticals Investigation Notice: SueWallSt Notifies Investors of Pending Investigation Into Xenon Pharmaceuticals (XENE)

September 22 at 6:18 PM | prnewswire.com

Xenon Pharmaceuticals: Azetukalner Still Has Potential As An Epilepsy Candidate

September 22 at 9:00 AM | seekingalpha.com

Wolf Popper LLP Announces Investigation on Behalf of Xenon Pharmaceuticals Inc. Investors

September 22 at 7:47 AM | globenewswire.com

Xenon stock lost 30%, but the FDA story is more complicated

September 21 at 11:37 PM | msn.com

Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

September 21 at 4:30 PM | financialpost.comF

Xenon to Present at TD Cowen Novel Mechanisms in Neuropsychiatry & Epilepsy Summit

September 21 at 4:01 PM | globenewswire.com

Xenon shares slide more than 30% as company pauses psychiatry trial enrollment

September 21 at 1:36 PM | thepharmaletter.comT

Xenon Pharmaceuticals Stock Sinks 31% After Pausing Depression Study Enrollment

September 21 at 1:36 PM | finance.yahoo.com

Xenon Pharmaceuticals (NASDAQ:XENE) Sees Unusually-High Trading Volume - Time to Buy?

September 21 at 12:19 PM | marketbeat.com

Xenon Pharmaceuticals Inc (XENE)

September 20, 2026 | za.investing.com

Robert W. Baird Issues Pessimistic Forecast for Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price

September 20, 2026 | americanbankingnews.com

Needham & Company LLC Has Lowered Expectations for Xenon Pharmaceuticals (NASDAQ:XENE) Stock Price

September 20, 2026 | americanbankingnews.com

Royal Bank Of Canada Lowers Xenon Pharmaceuticals (NASDAQ:XENE) Price Target to $70.00

September 20, 2026 | americanbankingnews.com

Wedbush Lowers Xenon Pharmaceuticals (NASDAQ:XENE) Price Target to $55.00

September 20, 2026 | americanbankingnews.com

Goldman Sachs Sticks to Its Buy Rating for Xenon (XENE)

September 19, 2026 | theglobeandmail.com

Why Xenon Pharmaceuticals (XENE) Is Down 32.2% After Pausing Psychiatry Trials Despite Positive NDA Data

September 19, 2026 | finance.yahoo.com

Xenon Pharmaceuticals (NASDAQ:XENE) Downgraded to "Strong Sell" Rating by Wall Street Zen

September 19, 2026 | marketbeat.com

Xenon: The Psychiatry Pause Matters More Than You Think (Rating Downgrade)

September 18, 2026 | seekingalpha.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

JANX, CELC, ABCL, and XENE Company Descriptions

AbCellera Biologics NASDAQ:ABCL

$12.31 -0.34 (-2.69%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$12.24 -0.08 (-0.61%)

As of 06:06 AM Eastern

AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.

Celcuity NASDAQ:CELC

$79.99 -4.11 (-4.89%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$80.01 +0.02 (+0.03%)

As of 05:42 AM Eastern

Celcuity Inc., a clinical stage biotechnology company, focuses on the development of targeted therapies for the treatment of various solid tumors in the United States. The company's CELsignia diagnostic platform uses a patient's living tumor cells to identify the specific abnormal cellular process driving a patient's cancer and the related targeted therapy for the treatment. Its drug candidate includes Gedatolisib, which selectively targets various class I isoforms of PI3K and mammalian target of rapamycin and focus on the treatment of patients with hormone receptor positive, HER2-negative, advanced or metastatic breast cancer, and metastatic castration resistant prostate cancer. It had a license agreement with Pfizer, Inc. for the development and commercialization rights to Gedatolisib. The company was founded in 2011 and is headquartered in Minneapolis, Minnesota.

Janux Therapeutics NASDAQ:JANX

$16.52 -0.95 (-5.44%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$16.53 +0.01 (+0.04%)

As of 05:44 AM Eastern

Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma. Its development pipeline also consists of discovery stage products. The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates. Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.

Xenon Pharmaceuticals NASDAQ:XENE

$36.56 -2.53 (-6.47%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$36.75 +0.19 (+0.52%)

As of 05:15 AM Eastern

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest JANX, CELC, ABCL, and XENE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest JANX, CELC, ABCL, and XENE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

JANX, CELC, ABCL, and XENE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

JANX, CELC, ABCL, and XENE Company Descriptions

AbCellera Biologics NASDAQ:ABCL

Celcuity NASDAQ:CELC

Janux Therapeutics NASDAQ:JANX

Xenon Pharmaceuticals NASDAQ:XENE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest JANX, CELC, ABCL, and XENE Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest JANX, CELC, ABCL, and XENE Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

JANX, CELC, ABCL, and XENE Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

JANX, CELC, ABCL, and XENE Company Descriptions

AbCellera Biologics NASDAQ:ABCL

Celcuity NASDAQ:CELC

Janux Therapeutics NASDAQ:JANX

Xenon Pharmaceuticals NASDAQ:XENE

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools